Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유권 | * |
dc.contributor.author | 정성애 | * |
dc.contributor.author | 심기남 | * |
dc.date.accessioned | 2016-11-26T02:11:34Z | - |
dc.date.available | 2016-11-26T02:11:34Z | - |
dc.date.issued | 2008 | * |
dc.identifier.issn | 1598-9992 | * |
dc.identifier.other | OAK-18016 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/232842 | - |
dc.description.abstract | BACKGROUND/AIMS: Bismuth-based quadruple therapy for second-line eradication treatment achieves the eradication rate ranging from 70% to 81% due to antimicrobial resistance and poor compliance. The aim of this study was to compare the eradication rate of levofloxacin-based triple therapy with that of bismuth-based quadruple therapy in second-line Helicobacter pylori (H. pylori) eradication therapy. METHODS: Seventy-six outpatients with persistent H. pylori infection after first-line triple therapy were enrolled in this prospective randomized trial. The subjects were randomized to receive levofloxacin 300 mg, amoxicillin 1 g, and pantoprazole 20 mg, given twice daily for 7 days (LAP group), or metronidazole 500 mg twice, tetracycline 500 mg four times, and pantoprazole 20 mg twice, bismuth subcitrate 600 mg twice daily for 7 days (MTPB group). Eradication was confirmed with (13)C-urea breath test or rapid urease test 4 weeks after the cessation of therapy. RESULTS: Among Seventy-six patients initially included, eleven were lost during follow-up. The eradication rates, expressed as intention to treat (ITT) and per protocol (PP) analyses, were 51.6% and 53.3% in the LAP group, and 48.9% and 62.9% in the MTPB group, respectively. There was no significant difference in H. pylori eradication rates between the two groups (p=0.815 by ITT, p=0.437 by PP). LAP regimen was better tolerated than MTPB regimen with lower incidence of side effects (10.0% versus 31.4%, p=0.03). CONCLUSIONS: H. pylori eradication rates of levofloxacin-based triple therapy and bismuth-based quadruple therapy were not significantly different in second-line H. pylori eradication therapy, and low incidence of side effects was observed in levofloxacin-based triple therapy. | * |
dc.language | Korean | * |
dc.title | Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 51 | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 285 | * |
dc.relation.lastpage | 290 | * |
dc.relation.journaltitle | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | * |
dc.identifier.scopusid | 2-s2.0-58149333894 | * |
dc.author.google | Jung H.S. | * |
dc.author.google | Shim K.N. | * |
dc.author.google | Baik S.J. | * |
dc.author.google | Na Y.J. | * |
dc.author.google | Kang M.J. | * |
dc.author.google | Jung J.M. | * |
dc.author.google | Ha C.Y. | * |
dc.author.google | Jung S.A. | * |
dc.author.google | Yoo K. | * |
dc.contributor.scopusid | 유권(7202592827) | * |
dc.contributor.scopusid | 정성애(7403676915) | * |
dc.contributor.scopusid | 심기남(13604838300) | * |
dc.date.modifydate | 20240415140437 | * |